The current immunotherapy strategy for breast cancer is limited. Tumor neoantigens have been proven to be a promising biomarker and potential target of immunotherapy in a variety of tumors. However, t
Table S1. Systematic multivariate analysis of mutational load comparing nulliparous vs. parous, early parous vs. late parous and PABC vs. nulliparous patients. Table S2. Systematic multivariate analys
Basal-like breast cancer is an aggressive subtype generally characterized as poor prognosis and lacking the expression of the three most important clinical biomarkers, estrogen receptor, progesterone
